TA
Takeda
TAK·NYSETokyo JPFounded 178149,000 employees
Large CappharmaPublicRare DiseaseOncologyNeurologyGI
Platform: Bio & Plasma
Market Cap
$48B
All Drugs
10
Clinical Trials
17
Failed / Terminated
4
FDA Approved
0
Stock Price & Catalysts (TAK)
Loading TAK stock data...
Drug Pipeline (10 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| TAK-1836 | TAK-1836 | Preclinical | 2 | EGFR | Prostate CaMCL | ||
| TAK-8730 | TAK-8730 | Phase 2 | 1 | VEGF | Breast CaCholangiocarcinoma | ||
| TAK-2403 | TAK-2403 | Phase 2 | 1 | WEE1 | FSGSWilms | ||
| TAK-9344 | TAK-9344 | Phase 3 | 3 | CGRP | ThymomaOCD | ||
| Fixainavolisib | TAK-8954 | Preclinical | 2 | CDK2 | Ovarian CaNASH | ||
| Tirasotorasib | TAK-9618 | NDA/BLA | 1 | IL-17A | CML | ||
| Tezecilimab | TAK-8016 | NDA/BLA | 2 | Tau | Parkinson'sMigraine | ||
| TAK-8262 | TAK-8262 | NDA/BLA | 2 | Tau | Hemophilia A | ||
| Lisorapivir | TAK-7853 | Preclinical | 2 | WRN | MCC | ||
| TAK-5300 | TAK-5300 | Phase 1 | 1 | SMN2 | Endometrial CaCML |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (13)